心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE
2015年
1期
84-87
,共4页
心肌梗死%血管成形术,气囊,冠状动脉%白细胞介素 17
心肌梗死%血管成形術,氣囊,冠狀動脈%白細胞介素 17
심기경사%혈관성형술,기낭,관상동맥%백세포개소 17
Myocardial infarction%Angioplasty,balloon,coronary%Interleukin-17
目的：观察丹红注射液对 ST 抬高型心肌梗死（STEMI）患者经皮冠状动脉介入术（PCI）术后白细胞介素17（IL-17）等表达的影响，并探讨其对 PCI 术后缺血-再灌注损伤（MIRI）的作用。方法：选择心内科行 PCI 治疗的 STEMI 患者300例，随机分为常规治疗组和丹红注射液治疗组，每组150例。采用酶联免疫法（ELISA）测定IL-17和 IL-6水平。结果：两组术前 IL-17和 IL-6表达水平无显著性差异（P ＞0.05），术后12h 两组 IL-17和 IL-6表达水平均显著升高（P ＜0.05），以后逐渐下降，术后72h 常规治疗组 IL-17和 IL-6表达水平仍然高于术前（P ＜0.05），但丹红组的已与术前无显著性差异（P ＞0.05）。丹红组临床治疗总有效率显著高于常规治疗组（92.7％比81.3％，P ＜0.05）。72h 时与常规治疗组比较，丹红组 IL-17[（31.4±6.1）ng／ml 比（23.2±4.3）ng／ml]和 IL-6[（60.3±11.6）ng／ml 比（42.7±8.4）ng／ml]水平显著降低，左室射血分数显著提高[（43.6±4.5）％比（53.7±5.6）％]，心肌梗死面积显著减小[（22.7±4.3）％比（17.2±3.7）％]，P 均＜0.05。结论：丹红注射液降低 IL-17和IL-6因子表达，可能是改善 PCI 术后 MIRI 的机制，从而缩小心肌梗死面积，改善心功能，具有临床推广应用价值。
目的：觀察丹紅註射液對 ST 抬高型心肌梗死（STEMI）患者經皮冠狀動脈介入術（PCI）術後白細胞介素17（IL-17）等錶達的影響，併探討其對 PCI 術後缺血-再灌註損傷（MIRI）的作用。方法：選擇心內科行 PCI 治療的 STEMI 患者300例，隨機分為常規治療組和丹紅註射液治療組，每組150例。採用酶聯免疫法（ELISA）測定IL-17和 IL-6水平。結果：兩組術前 IL-17和 IL-6錶達水平無顯著性差異（P ＞0.05），術後12h 兩組 IL-17和 IL-6錶達水平均顯著升高（P ＜0.05），以後逐漸下降，術後72h 常規治療組 IL-17和 IL-6錶達水平仍然高于術前（P ＜0.05），但丹紅組的已與術前無顯著性差異（P ＞0.05）。丹紅組臨床治療總有效率顯著高于常規治療組（92.7％比81.3％，P ＜0.05）。72h 時與常規治療組比較，丹紅組 IL-17[（31.4±6.1）ng／ml 比（23.2±4.3）ng／ml]和 IL-6[（60.3±11.6）ng／ml 比（42.7±8.4）ng／ml]水平顯著降低，左室射血分數顯著提高[（43.6±4.5）％比（53.7±5.6）％]，心肌梗死麵積顯著減小[（22.7±4.3）％比（17.2±3.7）％]，P 均＜0.05。結論：丹紅註射液降低 IL-17和IL-6因子錶達，可能是改善 PCI 術後 MIRI 的機製，從而縮小心肌梗死麵積，改善心功能，具有臨床推廣應用價值。
목적：관찰단홍주사액대 ST 태고형심기경사（STEMI）환자경피관상동맥개입술（PCI）술후백세포개소17（IL-17）등표체적영향，병탐토기대 PCI 술후결혈-재관주손상（MIRI）적작용。방법：선택심내과행 PCI 치료적 STEMI 환자300례，수궤분위상규치료조화단홍주사액치료조，매조150례。채용매련면역법（ELISA）측정IL-17화 IL-6수평。결과：량조술전 IL-17화 IL-6표체수평무현저성차이（P ＞0.05），술후12h 량조 IL-17화 IL-6표체수평균현저승고（P ＜0.05），이후축점하강，술후72h 상규치료조 IL-17화 IL-6표체수평잉연고우술전（P ＜0.05），단단홍조적이여술전무현저성차이（P ＞0.05）。단홍조림상치료총유효솔현저고우상규치료조（92.7％비81.3％，P ＜0.05）。72h 시여상규치료조비교，단홍조 IL-17[（31.4±6.1）ng／ml 비（23.2±4.3）ng／ml]화 IL-6[（60.3±11.6）ng／ml 비（42.7±8.4）ng／ml]수평현저강저，좌실사혈분수현저제고[（43.6±4.5）％비（53.7±5.6）％]，심기경사면적현저감소[（22.7±4.3）％비（17.2±3.7）％]，P 균＜0.05。결론：단홍주사액강저 IL-17화IL-6인자표체，가능시개선 PCI 술후 MIRI 적궤제，종이축소심기경사면적，개선심공능，구유림상추엄응용개치。
Objective:To observe the influence of Danhong injection on interleukin-17 (IL-17)expression after percu-taneous coronary intervention (PCI)in patients with ST segment elevation myocardial infarction (STEMI),and ex-plore its protective effect on myocardial ischemia-reperfusion injury (MIRI)after PCI.Methods:A total of 300STEMI patients undergoing PCI in department of cardiology were selected.They were randomly divided into routine treatment group (n=150)and Danhong injection group (n=150).Enzyme linked immunosorbent assay (ELISA) was used to measure levels of IL-17 and IL-6. Results:There were no significant difference in expression levels of IL-17 and IL-6 between two groups before PCI (P >0.05).On 12h after PCI,IL-17 levels of two groups signifi-cantly rose (P <0.05),then gradually declined,IL-17 and IL-6 levels in routine treatment group were still signifi-cantly higher than those of before PCI (P <0.05),but those of Danhong group were not significantly different from before PCI (P >0.05).Total effective rate of Danhong group was significantly higher than that of routine treat-ment group (92.7% vs.81.3%,P <0.05).Compared with routine treatment group on 72h after PCI,there were significant reductions in levels of IL-17 [(31.4±6.1)ng/ml vs.(23.2±4.3)ng/ml]and IL-6 [(60.3±11.6)ng/ml vs.(42.7±8.4)ng/ml],significant rise in left ventricular ejection fraction [(43.6±4.5)% vs.(53.7±5.6)%] and significant reduction in myocardial infarction area [(22.7±4.3)% vs.(17.2±3.7)%]in Danhong injection group,P <0.05 all.Conclusion:Danhong injection decreases expressions of IL-17 and IL-6,it may be mechanism improving MIRI after PCI,thereby diminishes myocardial infarction area,and improves heart function,which is worthy extending.
